SmartCella Holding AB
Alden Kandic is a seasoned professional in quality assurance and management within the pharmaceutical industry, currently serving as the Head of Quality and Vice President at Procella Therapeutics AB since May 2022. Prior experience includes leadership roles at Sobi - Swedish Orphan Biovitrum AB (publ) from November 2013 to May 2022, where Alden held multiple positions including Head of QA Haematology, Qualified Person, and Director of QA for Haemophilia. Additional experience encompasses quality assurance roles at Crucell Sweden AB, Apoteket Produktion & Laboratorier, and Diamyd Medical. Alden Kandic holds a Master of Science degree from Mälardalen University, completed in 2009.
This person is not in any teams
SmartCella Holding AB
SmartCella, founded in 2014, is an innovative biotechnology company based in Stockholm, Sweden. SmartCella’s vision is to combine first-in-class delivery platforms with cutting-edge cell and gene therapies to unleash the full potential of targeted therapies. The company has three main business units, Smartwise, SmartCella Solutions and Procella. Smartwise is developing and manufacturing a first-in-class endovascular delivery device, the Extroducer, that enables direct tissue/organ infusions through the vessel wall directly into to hard-to-reach organs and tumors. There is a significant unmet need in the field of targeted delivery of different types of therapies for regeneration of tissue and for treatment of cancer tumors. Smartwise received regulatory approval from the US FDA for the Extroducer in June 2022 and is now actively out-licensing the technology to global companies with therapies that benefit from direct delivery. SmartCella Solutions create novel mRNA therapies and platforms that enable cell-mediated delivery of protein and mRNA to specific regions, even within organs or microenvironments. A pipeline of projects within regeneration and tolerization, focusing on oncology, is in pre-clinical development. Procella has advanced capabilities within stem cell therapy development and inhouse cGMP manufacturing of cell based therapies, with a proven platform to take stem cell projects from discovery phase to clinical development. A globally licensed cardiac stem cell therapy is entering clinical stages (in collaboration with AstraZeneca) and there is a growing pipeline of projects in different stages of development, with dopamine producing cells for Parkinson´s Disease and our own iMSCs most advanced.